PCSK9 and familial hyperaldosteronism: This is the first study to demonstrate that the correlation between LDL‐C and PCSK9 levels could be modulated by GOF variants of PCSK9 among FH patients “under LLT.” This implies that the GOF variants of PCSK9 may be considered as a molecular marker in additional treatments in FH patients.